FDA OKs Nivolumab After Surgery for Esophageal or GEJ Cancer FDA OKs Nivolumab After Surgery for Esophageal or GEJ Cancer

The adjuvant use of nivolumab has been described as practice-changing in patients with resected esophageal or gastroesophageal junction cancer who have received chemoradiotherapy before surgery.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news